


EscharEx®

Next-Generation Enzymatic Debridement
for Chronic Wounds




New SOC Candidate

Modalities by Efficacy and Complexity




Superior Outcomes*

Debridement



Wound Bed Preparation



*Shoham et al. 2024; LANCET's eClinicalMedicine

Rapid Debridement

VLU Venous Leg Ulcers



DFU Diabetic Foot Ulcers



- Investigational drug containing a sterile mixture of proteolytic enzymes
- Debrides chronic wounds in 4-8 applications
- Easy to use topical application for all patient settings
- Promotes healthy granulation tissue, reduces biofilm and bacteria
- Demonstrated superiority over SANTYL®

- In line with current treatment and reimbursement practices
- De-risked program, based on validated technology and 3 successful Phase II studies
- Phase III for VLU; Planned phase II/III for DFU
- R&D collaborations with Mölnlycke, Solventum, and MIMEDX